Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Olema Pharmaceuticals, Inc. Common Stock (OLMA)

Pharmaceutical Preparations

https://www.olema.com

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.

780 BRANNAN STREET
SAN FRANCISCO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/19/2020

Market Cap

687,769,464

Shares Outstanding

54,770,000

Weighted SO

54,769,800

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

SANA --.--%

CGEM --.--%

LIFE --.--%

ZNTL --.--%

MOLN --.--%

MLYS --.--%

ANTX --.--%

PHVS --.--%

PEPG --.--%

Beta

2.0720

Last Div

0.0000

Range

8.5-17.791

Chg

-0.3800

Avg Vol

934975

Mkt Cap

687769464

Exch

NASDAQ

Country

US

Phone

650 243 5555

DCF Diff

10.5487

DCF

1.4614

Div Yield

0.0000

P/S

365.0581

EV Multiple

-5.5484

P/FV

2.9756

Div Yield %

0.0000

P/E

-6.1660

PEG

-0.3758

Payout

0.0000

Current Ratio

9.1271

Quick Ratio

9.1271

Cash Ratio

0.6366

DSO

159.0579

DIO

0.0000

Op Cycle

159.0579

DPO

4414.4722

CCC

-4255.4144

Gross Margin

0.8089

Op Margin

-64.5579

Pretax Margin

-58.1879

Net Margin

-58.1879

Eff Tax Rate

0.0044

ROA

-0.4307

ROE

-0.4418

ROCE

-0.5334

NI/EBT

1.0000

EBT/EBIT

0.9013

EBIT/Rev

-64.5579

Debt Ratio

0.0077

D/E

0.0086

LT Debt/Cap

0.0038

Total Debt/Cap

0.0086

Int Coverage

-92.4217

CF/Debt

-47.0291

Equity Multi

1.1206

Rec Turnover

2.2948

Pay Turnover

0.0827

Inv Turnover

0.0000

FA Turnover

0.6829

Asset Turnover

0.0074

OCF/Share

-1.6394

FCF/Share

-1.6423

Cash/Share

4.2483

OCF/Sales

-48.9761

FCF/OCF

1.0017

CF Coverage

-47.0291

ST Coverage

-83.6546

CapEx Coverage

-580.3208

Div&CapEx Cov

-580.3208

P/BV

2.9756

P/B

2.9756

P/S

365.0581

P/E

-6.1660

P/FCF

-7.4410

P/OCF

-7.3257

P/CF

-7.3257

PEG

-0.3758

P/S

365.0581

EV Multiple

-5.5484

P/FV

2.9756

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 05, 12:27 Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies GlobeNewswire Inc. Dec 04, 16:29 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 28, 17:10 Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS) GlobeNewswire Inc. Nov 02, 16:32 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revenue Product Segmentation